Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 1/2018

01-01-2018 | Short Communication

Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion

Authors: Meike Schneider, Katja Dinkelborg, Xiuli Xiao, Gayun Chan-Smutko, Kathleen Hruska, Dongli Huang, Pallavi Sagar, Mukesh Harisinghani, Othon Iliopoulos

Published in: Familial Cancer | Issue 1/2018

Login to get access

Abstract

Birt-Hogg-Dube (BHD) disease is an autosomal dominant cancer syndrome characterized by benign skin tumors, renal cancer and spontaneous pneumothorax and is caused by mutations in the Folliculin (FLCN) gene. Benign skin tumors and pneumothorax occur in the majority of patients affected by BHD syndrome, but only 30–45% of them develop renal cell carcinoma (RCC) with a median age of diagnosis at 48. The earliest onset of RCC in a BHD patient has been reported at age 20. Here we report a case of a 14 year-old patient with germline FLCN mutation leading to an early-onset bulky RCC that could not be classified strictly according to existing histological types. Germline genetic testing revealed a deletion at FLCN exon 5. The father of the patient was identified as the asymptomatic carrier. We report the youngest patient with BHD-related RCC. This early onset presentation supports genetic testing of at-risk patients and initiation of imaging surveillance for RCC in early adolescence. In addition, future studies are necessary to understand the determinants of reduced penetrance in BHD disease.
Literature
1.
Birt AR, Hogg GR, Dube WJ (1977) Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 113:1674–1677CrossRefPubMed
2.
Toro JR, Wei MH, Glenn GM et al (2008) BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. J Med Genet 45:321–331CrossRefPubMedPubMedCentral
3.
Kunogi M, Kurihara M, Ikegami TS et al (2010) Clinical and genetic spectrum of Birt-Hogg-Dube syndrome patients in whom pneumothorax and/or multiple lung cysts are the presenting feature. J Med Genet 47:281–287CrossRefPubMedPubMedCentral
4.
Benusiglio PR, Giraud S, Deveaux S et al (2014) Renal cell tumour characteristics in patients with the Birt-Hogg-Dube cancer susceptibility syndrome: a retrospective, multicentre study. Orphanet J Rare Dis 9:163CrossRefPubMedPubMedCentral
5.
Schmidt LS, Nickerson ML, Warren MB et al (2005) Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet 76:1023–1033CrossRefPubMedPubMedCentral
6.
Pavlovich CP, Walther MM, Eyler RA et al (2002) Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol 26:1542–1552CrossRefPubMed
7.
Pavlovich CP, Grubb RL 3rd, Hurley K et al (2005) Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol 173:1482–1486CrossRefPubMed
8.
Menko FH, van Steensel MA, Giraud S et al (2009) Birt-Hogg-Dube syndrome: diagnosis and management. Lancet Oncol 10:1199–1206CrossRefPubMed
9.
Argani P, Hicks J, De Marzo AM et al (2010) Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol 34:1295–1303CrossRefPubMedPubMedCentral
10.
Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol 70:93–105
11.
Amin MB, Gupta R, Ondrej H et al (2009) Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm. Am J Surg Pathol 33:393–400CrossRefPubMed
12.
Gunji Y, Akiyoshi T, Sato T et al (2007) Mutations of the Birt Hogg Dube gene in patients with multiple lung cysts and recurrent pneumothorax. J Med Genet 44:588–593CrossRefPubMedPubMedCentral
13.
Houweling AC, Gijezen LM, Jonker MA et al (2011) Renal cancer and pneumothorax risk in Birt-Hogg-Dube syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families. Br J Cancer 105:1912–1919CrossRefPubMedPubMedCentral
14.
Johannesma PC, van den Borne BE, Gille JJ et al (2014) Spontaneous pneumothorax as indicator for Birt-Hogg-Dube syndrome in paediatric patients. BMC Pediatr 14:171CrossRefPubMedPubMedCentral
15.
Bruder E, Passera O, Harms D et al (2004) Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 28:1117–1132CrossRefPubMed
16.
Wu A, Kunju LP, Cheng L, Shah RB (2008) Renal cell carcinoma in children and young adults: analysis of clinicopathological, immunohistochemical and molecular characteristics with an emphasis on the spectrum of Xp11.2 translocation-associated and unusual clear cell subtypes. Histopathology 53:533–544CrossRefPubMed
17.
18.
19.
Nickerson ML, Warren MB, Toro JR et al (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2:157–164CrossRefPubMed
20.
Benhammou JN, Vocke CD, Santani A et al (2011) Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dube syndrome. Genes Chromosomes Cancer 50:466–477CrossRefPubMedPubMedCentral
21.
Ding Y, Zhu C, Zou W et al (2015) FLCN intragenic deletions in Chinese familial primary spontaneous pneumothorax. Am J Med Genet A 167A:1125–1133CrossRefPubMed
22.
Lim DH, Rehal PK, Nahorski MS et al (2010) A new locus-specific database (LSDB) for mutations in the folliculin (FLCN) gene. Hum Mutat 31:E1043–E1051CrossRefPubMed
23.
Vocke CD, Yang Y, Pavlovich CP et al (2005) High frequency of somatic frameshift BHD gene mutations in Birt-Hogg-Dube-associated renal tumors. J Natl Cancer Inst 97:931–935CrossRefPubMed
24.
Kim JH, Seo SI, Song C, Chung J, Kwak C, Hong SH (2015) Clinicohistological characteristics of renal cell carcinoma in children: a multicentre study. Can Urol Assoc J 9:E705–E708CrossRefPubMedPubMedCentral
25.
Metadata
Title
Early onset renal cell carcinoma in an adolescent girl with germline FLCN exon 5 deletion
Authors
Meike Schneider
Katja Dinkelborg
Xiuli Xiao
Gayun Chan-Smutko
Kathleen Hruska
Dongli Huang
Pallavi Sagar
Mukesh Harisinghani
Othon Iliopoulos
Publication date
01-01-2018
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-0008-8

Other articles of this Issue 1/2018

Familial Cancer 1/2018 Go to the issue

Review

The role of screening MRI in the era of next generation sequencing and moderate-risk genetic mutations

Original Article

Association of genetic variations in RTN4 3′-UTR with risk for clear cell renal cell carcinoma

Short Communication

Gestational choriocarcinoma associated with a germline TP53 mutation

Short Communication

Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome

Original Article

How do clinical genetics consent forms address the familial approach to confidentiality and incidental findings? A mixed-methods study

Review

The association of low penetrance genetic risk modifiers with colorectal cancer in lynch syndrome patients: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits